• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Smith Gordon

    4/2/25 1:46:09 PM ET
    $HUM
    Medical Specialities
    Health Care
    Get the next $HUM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Smith Gordon

    (Last) (First) (Middle)
    HUMANA INC.
    500 W. MAIN ST

    (Street)
    LOUISVILLE KY 40202

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    HUMANA INC [ HUM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/31/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Humana Common(1) 765(1) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (2) (2) (2) Humana Common 783 783(2) D
    Restricted Stock Units (3) 03/31/2025 A 118 (3) (3) Humana Common 118 $263.875 118 D
    Explanation of Responses:
    1. Right to receive one share per restricted stock unit pursuant to the Company's 2019 Amended & Restated Stock Incentive Plan. Includes 765 restricted stock units representing a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3).
    2. Annual Director's fee payable in stock units which have been deferred at the election of the Reporting Person until his resignation of services as a director at which time the stock units will be payable in Humana Inc. common stock on a 1-for-1 basis, exempt pursuant to Rule 16(b)-3(d)(1). Includes 783 restricted stock units which represent a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1)&(3) under the Company's 2019 Amended & Restated Plan.
    3. Director's cash fee elected to be converted into stock units, deferred at the election of the Reporting Person during a designated enrollment period in the year preceding the reported transactions. Stock units will be payable in Humana Inc. common stock on a 1-for-1basis, exempt pursuant to Rule 16(b)-3(d)(1), per the Director's election.
    Gordon Smith 04/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HUM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HUM

    DatePrice TargetRatingAnalyst
    5/1/2025$315.00Mkt Perform → Outperform
    Raymond James
    11/6/2024$247.00 → $308.00Underperform → Neutral
    BofA Securities
    10/11/2024Sector Weight
    KeyBanc Capital Markets
    10/8/2024$308.00Mkt Perform → Outperform
    Bernstein
    10/7/2024$402.00 → $261.00Buy → Hold
    TD Cowen
    10/7/2024$519.00 → $253.00Buy → Hold
    Jefferies
    10/3/2024$392.00 → $274.00Overweight → Neutral
    Piper Sandler
    10/2/2024$376.00 → $247.00Neutral → Underperform
    BofA Securities
    More analyst ratings

    $HUM
    Leadership Updates

    Live Leadership Updates

    See more
    • Humana Announces CFO Transition

      Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that Celeste Mellet will be appointed to succeed Susan Diamond as Chief Financial Officer (CFO), effective January 11, 2025. Diamond is stepping down after a successful 18-year career at Humana, including over three years as CFO, and will serve in an advisory role through the end of 2025 to ensure a smooth transition. "On behalf of the entire Board and management team, I want to extend my thanks to Susan for her leadership as CFO and in prior roles during her nearly two decades at Humana," said Jim Rechtin, Humana's President and Chief Executive Officer. "Susan's contributions spanned across our Medicare, Home So

      12/3/24 8:05:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Appoints Michelle O'Hara as Chief Human Resources Officer

      Leading health and well-being company Humana Inc. (NYSE:HUM) announced today that it has named Michelle O'Hara as Chief Human Resources Officer, effective January 1, 2025. O'Hara will oversee the enterprise talent strategy and people programs for Humana's more than 63,000 employees. She brings a proven track record of transforming HR capabilities and enabling companies to effectively attract, recruit, develop and retain a talented and diverse workforce. O'Hara will report directly to Humana President and CEO Jim Rechtin. "Humana's people strategy is a core capability for our business that supports and empowers our workforce so they can successfully deliver on our mission to make it easier

      11/12/24 12:30:00 PM ET
      $HUM
      Medical Specialities
      Health Care
    • Define Ventures Appoints Bruce Broussard as Venture Partner

      The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie

      10/22/24 9:00:00 AM ET
      $EVH
      $HIMS
      $HUM
      Other Consumer Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care

    $HUM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CenterWell Specialty Pharmacy Takes National Patient Choice Award

      Organization Recognized for Seventh Time in Eight Years CenterWell Specialty Pharmacy has once again received the MMIT Specialty Pharmacy Patient Choice Award in the PBM/Payer category, its seventh such win in the past eight years. The award recognizes best-in-class customer satisfaction and commitment to patient care by a specialty pharmacy. "There's something so rewarding about seeing our team's dedication to excellent care and support being recognized year after year by the people we serve," said Guillermo Sollberger, senior vice president of CenterWell Specialty Pharmacy and CenterWell Pharmacy. "We know that many of the patients who require specialty drugs are feeling overwhelmed, so

      5/13/25 9:00:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Reports First Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted Financial Guidance

      Reports 1Q25 earnings per share (EPS) of $10.30 on a GAAP basis, Adjusted EPS of $11.58 1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent' Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88' Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties Remains confident

      4/30/25 6:00:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Board Declares Payment of Quarterly Dividend to Stockholders

      Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on July 25, 2025 to stockholders of record as of the close of business on June 27, 2025. About Humana Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military serv

      4/17/25 6:30:00 AM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mesquita Jorge S. bought $200,066 worth of Humana Common (545 units at $367.09) (SEC Form 4)

      4 - HUMANA INC (0000049071) (Issuer)

      2/21/24 10:37:23 AM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $HUM
    SEC Filings

    See more

    $HUM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $HUM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Smith Gordon

      4 - HUMANA INC (0000049071) (Issuer)

      4/2/25 1:46:09 PM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Hilzinger Kurt J

      4 - HUMANA INC (0000049071) (Issuer)

      4/2/25 1:45:12 PM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Feinberg David T

      4 - HUMANA INC (0000049071) (Issuer)

      4/2/25 1:44:32 PM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Humana Inc.

      10-Q - HUMANA INC (0000049071) (Filer)

      4/30/25 9:29:51 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HUMANA INC (0000049071) (Filer)

      4/30/25 6:05:50 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - HUMANA INC (0000049071) (Filer)

      4/18/25 4:20:41 PM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Humana Inc. (Amendment)

      SC 13G/A - HUMANA INC (0000049071) (Subject)

      2/16/24 4:29:43 PM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Humana Inc. (Amendment)

      SC 13G/A - HUMANA INC (0000049071) (Subject)

      2/14/24 10:02:59 AM ET
      $HUM
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Humana Inc. (Amendment)

      SC 13G/A - HUMANA INC (0000049071) (Subject)

      2/13/24 5:06:27 PM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana upgraded by Raymond James with a new price target

      Raymond James upgraded Humana from Mkt Perform to Outperform and set a new price target of $315.00

      5/1/25 7:42:13 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana upgraded by BofA Securities with a new price target

      BofA Securities upgraded Humana from Underperform to Neutral and set a new price target of $308.00 from $247.00 previously

      11/6/24 8:21:46 AM ET
      $HUM
      Medical Specialities
      Health Care
    • KeyBanc Capital Markets initiated coverage on Humana

      KeyBanc Capital Markets initiated coverage of Humana with a rating of Sector Weight

      10/11/24 7:47:34 AM ET
      $HUM
      Medical Specialities
      Health Care

    $HUM
    Financials

    Live finance-specific insights

    See more
    • Humana Reports First Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted Financial Guidance

      Reports 1Q25 earnings per share (EPS) of $10.30 on a GAAP basis, Adjusted EPS of $11.58 1Q25 Insurance segment benefit ratio of 87.4 percent, in line with the company's previously disclosed expectation of 'approximately 87.5 percent' Affirms Adjusted FY 2025 EPS guidance of 'approximately $16.25'; while revising GAAP EPS to 'approximately $14.68' from the previous estimate of 'approximately $15.88' Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent Affirms expected individual Medicare Advantage annual membership decline of approximately 550,000, inclusive of the impact of exiting certain unprofitable plans and counties Remains confident

      4/30/25 6:00:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Board Declares Payment of Quarterly Dividend to Stockholders

      Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on July 25, 2025 to stockholders of record as of the close of business on June 27, 2025. About Humana Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military serv

      4/17/25 6:30:00 AM ET
      $HUM
      Medical Specialities
      Health Care
    • Humana Inc. Announces Dates for First Quarter 2025 Earnings and June Investor Conference

      Humana Inc. (NYSE:HUM) will release financial results for the first quarter 2025 (1Q25) and host a live question-and-answer session on Wednesday, April 30, 2025. Additionally, the company will host an Investor Conference on Monday, June 16, 2025. 1Q25 Earnings Humana will release its 1Q25 financial results, as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on April 30, 2025. The company will host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2025. A webcast of the 1Q25 earnings call may be accessed via Humana's Investor Relations page at https://humana.gc

      4/3/25 4:15:00 PM ET
      $HUM
      Medical Specialities
      Health Care